Literature DB >> 8862724

The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.

B B Hasinoff1, J C Yalowich, Y Ling, J L Buss.   

Abstract

Dexrazoxane (ICRF-187) is clinically used to reduce doxorubicin-induced cardiotoxicity. Because dexrazoxane, doxorubicin and daunorubicin all act on DNA topoisomerase II, a study was undertaken to see what effect dexrazoxane had on the growth inhibitory effects of doxorubicin and daunorubicin towards Chinese hamster ovary cells. Dexrazoxane exhibited significant antagonism of doxorubicin- and daunorubicin-mediated growth inhibition when the cells were preincubated with dexrazoxane before the anthracycline was added. Continuous exposure of cells to either anthracycline and low concentrations of dexrazoxane resulted in additive growth inhibitory effects at low anthracycline concentrations, and no effect at higher anthracycline concentrations.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8862724     DOI： 10.1097/00001813-199607000-00011

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN： 0959-4973            Impact factor:   2.248


  6 in total

1.  Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism.

Authors:  Fang Zhou; Gang Hao; Jingwei Zhang; Yuanting Zheng; Xiaolan Wu; Kun Hao; Fang Niu; Dan Luo; Yuan Sun; Liang Wu; Wencai Ye; Guangji Wang
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.

Authors:  H Kaiserová; G J M den Hartog; T Simůnek; L Schröterová; E Kvasnicková; A Bast
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

Review 3.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

4.  Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Authors:  Anna Vavrova; Hana Jansova; Eliska Mackova; Miloslav Machacek; Pavlina Haskova; Lucie Tichotova; Martin Sterba; Tomas Simunek
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

5.  Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.

Authors:  Lars H Jensen; Marielle Dejligbjerg; Lasse T Hansen; Morten Grauslund; Peter B Jensen; Maxwell Sehested
Journal:  BMC Pharmacol       Date:  2004-12-02

6.  Modulatory Effect of Betulinic Acid on the Genotoxicity Induced by Different Mutagens in V79 Cells.

Authors:  Nathália Oliveira Acésio; Pollyanna Francielli de Oliveira; Daiane Fernanda Pereira Mastrocola; Ildercílio Mota de Souza Lima; Carla Carolina Munari; Vânia Luiza Ferreira Lucatti Sato; Andressa Aparecida Silva Souza; Lúzio Gabriel Bocalon Flauzino; Wilson Roberto Cunha; Denise Crispim Tavares
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-19       Impact factor: 2.629
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.